이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Eton Pharmaceuticals 배당금

배당금 기준 확인 0/6

Eton Pharmaceuticals 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.2%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$0.26
배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Sep 10

Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

Jan 09

The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Dec 13

Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Nov 16

Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Sep 30

Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Jul 25

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Jun 29

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Dec 22

Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous

Sep 13

Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story

Aug 14

Eton Pharma jumps 20% on FDA approval of seizure therapy

Jul 18

Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Apr 15

Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Oct 14

Another Look At Eton Pharmaceuticals

Sep 03

What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Aug 18

Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Mar 01

Eton Pharma buys Canadian rights for Alkindi Sprinkle

Jan 14

Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

Jan 07

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 ETON 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: ETON 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Eton Pharmaceuticals 시장 대비 배당 수익률

ETON 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (ETON)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Pharmaceuticals)	2.2%
애널리스트 예측 (ETON) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ETON 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ETON 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ETON 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: ETON 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Eton Pharmaceuticals 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Eton Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Eton Pharmaceuticals Announces Fda Acceptance of New Drug Application for Et-400 (Hydrocortisone Oral Solution)

First quarter 2024 earnings: EPS exceeds analyst expectations

Eton Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Eton Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2024

Insufficient new directors

New minor risk - Market cap size

Full year 2023 earnings: EPS and revenues miss analyst expectations

Eton Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Eton Pharmaceuticals Awards U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

Investor sentiment deteriorates as stock falls 17%

Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Consensus EPS estimates have been upgraded.

Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Investor sentiment deteriorates as stock falls 19%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Eton Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New minor risk - Market cap size

Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Price target increased by 11% to US$10.00

Eton Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Eton Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New minor risk - Share price stability

Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Price target decreased by 10.0% to US$9.00

Eton Pharmaceuticals, Inc. Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Eton Pharmaceuticals, Inc. Announces Commercial Availability of Betaine Anhydrous for Oral Solution, A Generic Version of Cystadane® (Betaine Anhydrous for Oral Solutions)

Eton Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection

Consensus estimates of losses per share improve by 14%

Eton Pharmaceuticals, Inc Submits New Drug Application Response for Its Dehydrated Alcohol Injection Product Candidate to the U.S. Food and Drug Administration

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Forecast to breakeven in 2023

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Eton Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous

Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Eton Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$9.00

Eton Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves ZONISADE

Eton Pharma jumps 20% on FDA approval of seizure therapy

Eton Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Eton Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$10.50

Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Consensus forecasts updated

Eton Pharmaceuticals, Inc. Appoints James Gruber as Chief Financial Officer

Consensus revenue estimates increase by 11%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$10.00

Eton Pharmaceuticals Receives Notice from the Zonisamide Oral Suspension Product Candidate That the United States Food and Drug Administration (“Fda”) Has Scheduled an On-Site Inspection of the Facility Beginning

Eton Pharmaceuticals, Inc and ANI Pharmaceuticals, Inc Announce Commercial Availability of Carglumic Acid Tablets

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.31 loss in 3Q 2020)

Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Another Look At Eton Pharmaceuticals

Price target increased to US$14.00

Second quarter 2021 earnings released: US$0.08 loss per share (vs US$0.23 loss in 2Q 2020)

What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Eton Pharmaceuticals, Inc.(NasdaqGM:ETON) dropped from Russell 3000E Index

Eton Pharmaceuticals, Inc Acquires U.S. and Canadian Rights to Crossject's ZENEO Hydrocortisone Needleless Autoinjector

Eton Pharma wins FDA approval for Rezipres

Eton Pharmaceuticals, Inc Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection

Price target decreased to US$12.50

FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner